Krystal Biotech, Inc.
KRYS
$143.96
-$2.34-1.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 146.22% | 3,734.01% | 423.23% | -66.34% | 146.88% |
| Total Depreciation and Amortization | -65.86% | -9.84% | -59.41% | -45.63% | 5.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.98% | 65.58% | 39.99% | 113.86% | 27.96% |
| Change in Net Operating Assets | 101.48% | -394.16% | 78.25% | 291.78% | -181.74% |
| Cash from Operations | 1,365.09% | 94.92% | 830.68% | 377.29% | 87.81% |
| Capital Expenditure | -68.35% | -392.38% | 56.63% | 41.27% | 59.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 50.30% | -96.46% | -898.16% | -577.30% | -38.39% |
| Cash from Investing | 45.62% | -110.81% | -724.59% | -132.63% | -21.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -83.12% | -90.84% | -7.29% | -74.87% | -94.26% |
| Repurchase of Common Stock | -- | -158.60% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -83.12% | -217.79% | -7.29% | -74.87% | -94.26% |
| Foreign Exchange rate Adjustments | 414.24% | -8.56% | -324.29% | 2,283.33% | -4,312.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 440.84% | -5,423.75% | -95.14% | -71.06% | -109.78% |